LAIV administered intranasally closely mimics natural infection and stimulates robust IgA and IgG antibody responses; however, this vaccine failed to provide adequate protection against influenza A(H1N1)pdm09 during the 2013–2014 and 2015–2016 seasons (Grohskopf et al., 2016, 2018). The gene discussed is CD79A; the disease is infection.